Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.39 |
| ▸ | KCNJ1 | P48048 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488656 | 0.85 | GPR119 (0.67) | GPR119MAPTUSP2ALDH1A1HPGD | |
| SCHEMBL3488577 | 0.69 | GPR119 (0.70) | GPR119MAPTALDH1A1HPGD | |
| SCHEMBL1662735 | 0.69 | GPR119 (0.78) | GPR119MAPTUSP2ALDH1A1HPGD | |
| SCHEMBL1118284 | 0.69 | GPR119 (0.71) | GPR119TP53MAPTALDH1A1HPGD | |
| SCHEMBL3488667 | 0.69 | GPR119 (0.73) | GPR119MAPTUSP2ALDH1A1HPGD | |
| SCHEMBL3489235 | 0.69 | GPR119 (0.78) | GPR119MAPTUSP2ALDH1A1HPGD | |
| SCHEMBL3488276 | 0.68 | GPR119 (0.88) | GPR119TP53MAPT | |
| SCHEMBL1118437 | 0.68 | GPR119 (0.66) | GPR119AOC3MAPTUSP2ALDH1A1 | |
| SCHEMBL3489736 | 0.68 | GPR119 (0.46) | GPR119AOC3ALDH1A1HTT | |
| SCHEMBL1118273 | 0.68 | GPR119 (0.69) | GPR119TP53MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | CYMABAY THERAPEUTICS INC (US) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021335-A1 | HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS | GPR119, INSR, GLP1R | GPR119 1/4885AOC3 2070/4885KCNJ1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.